Test Price
1,200 AED✅ Home Collection Available
BCR-ABL1 Quantification by Droplet Digital PCR (ddPCR) in UAE | 1200 AED | DHA-Licensed Molecular Monitoring
Executive Summary & Core Metrics
Executive Summary
The BCR-ABL1 Quantification by Droplet Digital PCR (ddPCR) test is the established molecular gold standard for monitoring minimal residual disease (MRD) burden in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukemia (ALL). This assay delivers exceptional diagnostic sensitivity of 99.9% through our ISO 9001:2015 accredited laboratory (Cert: INT/EGQ/2509DA/3139), with results aligned to the WHO International Scale (IS). The test enables oncologists and hematologists to precisely track tyrosine kinase inhibitor (TKI) therapy response and detect molecular relapse before hematological progression occurs.
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- ✓ Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by qualified clinical counsellors.
- ✓ Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
Droplet Digital PCR Molecular Quantification
The BCR-ABL1 Quantification by Droplet Digital PCR (ddPCR) test measures the absolute copy number of the BCR-ABL1 fusion transcript in peripheral blood with unparalleled precision, enabling oncologists, hematologists, and preventive medicine specialists to monitor minimal residual disease (MRD) and assess tyrosine kinase inhibitor (TKI) therapy response at the molecular level. Unlike conventional real-time quantitative PCR (RT-qPCR) which relies on standard curve interpolation, ddPCR partitions the sample into approximately 20,000 individual nanodroplets. Each droplet functions as an independent PCR reactor, allowing direct counting of positive versus negative reactions to deliver an absolute concentration value in copies per microliter without external calibration.
| Feature | Our Test: ddPCR | Closest Alternative: RT-qPCR |
|---|---|---|
| Precision & Sensitivity | Absolute quantification; detection down to 0.001% IS (MR4.5) | Relative quantification; typical limit ~0.01% IS (MR4.0) |
| Methodology | Droplet Digital PCR — partitions sample into ~20,000 nanodroplets for independent amplification | Real-Time Quantitative PCR — bulk reaction with standard curve dependency |
| Turnaround Time | 2–3 Days | 3–5 Days (variable) |
| Standardisation | Aligned to International Scale (IS) via WHO reference panel | IS conversion required; inter-laboratory variability higher |
| Price | 1200 AED | 900–1100 AED (estimated) |
Physician Insight & Safety Protocols
Clinical Note from Lina Osama Zaki Quteineh — Consultant Medical Genetics, DHA Registration ID: 9294403:
"The BCR-ABL1 ddPCR assay represents a significant advancement in the precision of molecular monitoring for patients with CML and Ph+ ALL. The ability to detect minimal residual disease at the MR4.5 level provides clinicians with an early window into molecular relapse that may precede hematologic recurrence by several months. I must stress, however, that this test is one component of a comprehensive clinical evaluation. Treatment decisions, particularly TKI dose adjustments or eligibility for treatment-free remission protocols, must always integrate serial ddPCR trends with complete blood counts, bone marrow assessment when indicated, and the full clinical context under the guidance of an experienced hematologist or oncologist."
⚠ Medication Safety Advisory
Do not discontinue, reduce, or modify your prescribed tyrosine kinase inhibitor (TKI) therapy — including imatinib, dasatinib, nilotinib, bosutinib, ponatinib, or asciminib — without consulting your treating oncologist. Abrupt cessation of TKI therapy in patients with detectable molecular disease may precipitate accelerated-phase CML, blast crisis, or relapsed acute leukemia, all of which constitute medical emergencies requiring immediate hospitalisation. Serial ddPCR monitoring is designed to guide therapy while on treatment, not to support self-directed medication changes.
⚠ Exclusion Criteria & Emergency Red Flags
- Exclusion: This test is not validated for patients who have undergone allogeneic stem cell transplantation within the last 90 days (false-negative risk due to engraftment dynamics).
- Exclusion: Specimens with gross hemolysis (visual haemoglobin >500 mg/dL) will be rejected; repeat collection required.
- Emergency Red Flag: A >1-log increase in BCR-ABL1 transcript level between consecutive ddPCR assessments warrants urgent hematology-oncology consultation within 48 hours.
- Emergency Red Flag: New-onset fever, unexplained bruising, bone pain, or splenic discomfort in a known CML patient — seek emergency department evaluation immediately regardless of ddPCR result.
- Minors: Per Federal Decree-Law No. 4 of 2016 on Medical Liability, testing on patients under 18 requires explicit parental or legal guardian consent with valid government-issued identification.
Patient FAQ & Clinical Guidance
1. How is the BCR-ABL1 ddPCR test different from standard PCR, and why does it matter for my CML monitoring?
Droplet Digital PCR provides absolute quantification of BCR-ABL1 transcripts without requiring a standard curve, enabling detection of molecular relapse up to six months earlier than conventional RT-qPCR — this early warning allows your oncologist to intervene before hematological relapse occurs, directly impacting long-term treatment-free remission success rates. Unlike standard PCR which measures relative fluorescence against a calibration reference, ddPCR partitions your sample into approximately 20,000 individual nanodroplets where each droplet acts as an independent PCR reactor, counting positive versus negative droplets to deliver a precise copies-per-microliter result aligned to the WHO International Scale.
2. What should I do to prepare for the blood draw, and are there any medications I need to temporarily hold?
No fasting is required for BCR-ABL1 ddPCR testing; however, you must continue all prescribed TKI medications exactly as directed — never withhold a dose for the purpose of this blood test, as the assay specifically measures the molecular response achieved while on therapy, and interrupting treatment would produce clinically misleading results that could jeopardize your care. A valid doctor's prescription is mandatory prior to sample collection. Please note: this test result alone is not a substitute for comprehensive pre-surgical clearance documentation, pregnancy-related clinical assessment, or international travel fitness certification.
3. How long will my test result take, and can I receive clinical guidance after receiving the report?
Your BCR-ABL1 ddPCR result is delivered within 2 to 3 working days via secure digital report, and every patient is entitled to a complimentary telephonic post-test clinical guidance session where a qualified molecular diagnostics counsellor explains your IS percentage, log reduction milestone, and what the trend means in the context of your TKI therapy journey. This session ensures you understand your molecular response level before your next scheduled oncology appointment.
4. What does the International Scale (IS) percentage mean for my treatment plan?
The International Scale (IS) percentage represents your BCR-ABL1 transcript level normalized to a global standard. A result of 0.1% IS corresponds to a 3-log reduction (major molecular response, MMR), 0.01% IS to a 4-log reduction (MR4.0), and 0.001% IS to a 4.5-log reduction (MR4.5). Achieving and sustaining MR4.5 is a prerequisite for considering TKI discontinuation in clinical trials. Your oncologist will interpret these milestones in the context of your baseline risk profile, treatment duration, and overall clinical status.
5. Is this test suitable for initial diagnosis of CML, or only for monitoring?
The BCR-ABL1 ddPCR test is primarily validated for molecular monitoring of established CML or Ph+ ALL patients on TKI therapy. For initial diagnosis, conventional cytogenetic analysis (karyotyping) and fluorescence in situ hybridization (FISH) remain the frontline diagnostic methods. Once the diagnosis is confirmed and the BCR-ABL1 fusion transcript is identified, ddPCR becomes the optimal tool for serial quantification of residual disease burden and longitudinal treatment response assessment.
UAE Regulatory & Data Privacy Adherence
Federal Decree-Law No. 45 of 2021 (PDPL)
All patient genomic and molecular data is processed, stored, and transmitted in strict compliance with the UAE Personal Data Protection Law. Results are encrypted end-to-end and accessible only to the ordering physician and authorised patient portal. No third-party data sharing occurs without explicit patient consent as mandated under Articles governing health data processing.
Federal Law No. 2 of 2019 (ICT in Health)
Full compliance with all provisions governing the use of information and communication technology in health fields, including secure electronic health records, digital reporting standards, and telemedicine consultation frameworks. All ddPCR data transmission adheres to DHA and MOHAP interoperability standards for laboratory information systems.
Federal Decree-Law No. 4 of 2016 (Medical Liability)
All specimen collection, clinical testing, and result disclosure procedures strictly follow the Medical Liability Law, ensuring patient safety, informed consent, and professional accountability. Minor patient testing requires explicit parental or guardian authorisation with valid Emirates ID or passport prior to any sample collection.
ISO 9001:2015 Certification: INT/EGQ/2509DA/3139 • DHA Facility License: 1143 • Corporate Lab: DNA Labs UAE • Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE
Clinical & Logistical Metadata
| Test Name | BCR-ABL1 Quantification by Droplet Digital PCR (ddPCR) |
| Price (AED) | 1200 AED |
| Turnaround Time | 2–3 Working Days |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) — VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM |
| Methodology Used | Droplet Digital PCR (ddPCR) — Absolute quantification via nanodroplet partitioning, aligned to WHO International Scale |
| ICD-10-CM Code | C92.10, C91.00, Z85.6 |
| LOINC Code | 69380-8 |
| DHA Facility License & Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians